27 Jun 2008 07:00
Embargoed Release: 07:00hrs Friday 27 June 2008
PLETHORA SOLUTIONS HOLDINGS PLC
("Plethora Solutions" or "Plethora")
Board Change
Plethora Solutions Holdings PLC (AIM : PLE), the specialist developer of products for the treatment and management of urological disorders, announces a forthcoming change to its Board of Directors.
Brad Hoy is to step down as Chief Financial Officer in July 2008. He will be succeeded by David Ellam, formerly Group Financial Controller of specialist healthcare company Ark Therapeutics Group plc, who will join the Board as Chief Financial Officer upon Brad's departure.
Brad Hoy joined Plethora Solutions as Chief Financial Officer in 2005 and was instrumental in the Company's flotation on AIM and the subsequent acquisition of Timm Medical Technologies in 2006. Following on from the recent Paul Capital Healthcare transaction, Brad has provided the Company with a strong foundation for its continued development.
David Ellam, 44, was Group Financial Controller at Ark Therapeutics from October 2001 and prior to that he was Director of Financial Planning and Analysis within the Credit Card Division of Morgan Stanley. David qualified as a Chartered Accountant in 1989 with Coopers & Lybrand.
Stuart Wallis, Chairman of Plethora, commented:
"Brad has played a key role in transforming Plethora from an early stage development company to a specialty pharma business with a diversified, late-stage product portfolio. The Board and I would like to thank him for his important contribution to the business and wish him well for the future.
"I would like to welcome David Ellam to the Board. David has broad experience in many aspects of finance and in a range of industries and will play a key role in Plethora's growth plans over the coming years."
In accordance with Schedule Two paragraph (g) of the AIM rules, there are no additional disclosures to be made.
-Ends-
Enquiries:
| Plethora Solutions Steven Powell | Tel : +44(0) 20 3077 5400 |
| Hansard Group Adam Reynolds/John Bick | Tel: +44(0) 20 7245 1100 |
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc., which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based specialty sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE)
Further information is available at www.plethorasolutions.co.uk